Pharvaris N.V.
PHVSNasdaq
$34.94
↑ +3.8%Jul 17 close · end-of-day
Price
1Y↑ +51.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
No screener snapshot for this ticker.
Company profile
Pharvaris N.V. focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE) The company was incorporated in 2015 and is based in Leiden, the Netherlands.
- CEO
- Berndt A. E. Modig
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 30
- Website
- pharvaris.com
Management & directors
- Modig BerndtChief Executive Officer
- Lu PengChief Medical Officer
- Lesage AnneChief Early Development
- Nijdam AnnaPrincipal Accounting Officer
- Nassif David W.CFO / CLO
- Abele Stefan AndreasChief Technical Ops Officer
- Souverijns WimChief Commercial Officer
Roles derived from SEC Form 4 filings.
Earnings
No reported earnings periods on file.
Financial statements
No annual data.
No quarterly data.
Company news
Jul 15, 2026
Jul 6, 2026
- 14d agoWhy This Biotech, Up 12% Since Its Breakout, Yo-Yoed On A Key FDA Developmentfinance.yahoo.com
- 14d agoWhy This Biotech, Up 14% Since Its Breakout, Is On The Rise Once Againfinance.yahoo.com
- 14d agoPharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacksfinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-13 | Modig Berndt· Chief Executive Officer | Sale | 2,292 | $34.97 | $80,154.45 | filing |
| 2026-07-12 | Lu Peng· Chief Medical Officer | Tax withholding | 117 | $35.07 | $4,103.19 | filing |
| 2026-07-11 | Lu Peng· Chief Medical Officer | Tax withholding | 109 | $35.07 | $3,822.63 | filing |
| 2026-06-30 | Schikan Johannes Gerardus Christiaan Petrus | Sale | 30,712 | $35.49 | $1.1M | filing |
| 2026-06-30 | Lesage Anne· Chief Early Development | Sale | 30,703 | $35.49 | $1.1M | filing |
| 2026-06-30 | Lesage Anne· Chief Early Development | Sale | 27,872 | $35.48 | $988,890.20 | filing |
| 2026-06-30 | Lesage Anne· Chief Early Development | Option exercise | 24,900 | $8.05 | $200,445.00 | filing |
| 2026-06-30 | Lesage Anne· Chief Early Development | Option exercise | 2,972 | $2.59 | $7,697.48 | filing |
| 2026-06-29 | Lesage Anne· Chief Early Development | Sale | 8,300 | $35.05 | $290,907.53 | filing |
| 2026-06-29 | Lesage Anne· Chief Early Development | Sale | 6,997 | $35.05 | $245,231.56 | filing |
| 2026-06-29 | Schikan Johannes Gerardus Christiaan Petrus | Sale | 6,888 | $35.05 | $241,447.13 | filing |
| 2026-06-29 | Schikan Johannes Gerardus Christiaan Petrus | Sale | 2,400 | $35.10 | $84,249.84 | filing |
| 2026-06-29 | Lesage Anne· Chief Early Development | Sale | 2,300 | $35.12 | $80,785.66 | filing |
| 2026-06-29 | Lesage Anne· Chief Early Development | Option exercise | 4,200 | $8.05 | $33,810.00 | filing |
| 2026-06-29 | Lesage Anne· Chief Early Development | Option exercise | 4,100 | $2.59 | $10,619.00 | filing |
| 2026-06-29 | Lesage Anne· Chief Early Development | Option exercise | 900 | $8.05 | $7,245.00 | filing |
| 2026-06-29 | Lesage Anne· Chief Early Development | Option exercise | 1,400 | $2.59 | $3,626.00 | filing |
| 2026-06-26 | Lu Peng· Chief Medical Officer | Sale | 14,700 | $34.00 | $499,847.04 | filing |
| 2026-06-26 | Lu Peng· Chief Medical Officer | Option exercise | 14,700 | $2.59 | $38,073.00 | filing |
| 2026-06-25 | Lu Peng· Chief Medical Officer | Sale | 11,600 | $34.45 | $399,674.52 | filing |
| 2026-06-25 | Lu Peng· Chief Medical Officer | Sale | 3,400 | $35.09 | $119,310.42 | filing |
| 2026-06-25 | Lesage Anne· Chief Early Development | Sale | 2,300 | $35.12 | $80,785.66 | filing |
| 2026-06-25 | Lesage Anne· Chief Early Development | Sale | 2,300 | $35.12 | $80,774.62 | filing |
| 2026-06-25 | Lu Peng· Chief Medical Officer | Option exercise | 15,000 | $2.59 | $38,850.00 | filing |
| 2026-06-25 | Lesage Anne· Chief Early Development | Option exercise | 900 | $8.05 | $7,245.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.